Results 61 to 70 of about 70,330 (230)

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source

Integrating Human Intestinal Organoids into FDA'S New Approach Methodologies for Drug Discovery

Advanced Science, EarlyView.
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee, Honit Piplani, Aida Habtezion, Michael J. Rosen, Jospeh C. Wu   +6 more
wiley   +1 more source

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

Journal of Immunology Research, 2019
To improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library.
Weiyi Qiu, Chang Zhang, Shuang Wang, Xiaoyan Yu, Qiong Wang, Dadi Zeng, Peng Du, Jinling Ma, Yiqiong Zheng, Bo Pang, Yunzhou Yu, Feng Long, Xiaobin Pang, Zhiwei Sun   +13 more
doaj   +1 more source

Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer

Cancer Cell International, 2018
Background Primary or acquired resistance to cetuximab often occurs during targeted therapy in metastatic colorectal cancer (mCRC) patients. In many cancers, the key role of the long noncoding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) in ...
Ying-nan Yang, Rui Zhang, Jing-wen Du, Heng-heng Yuan, Yan-jing Li, Xiao-li Wei, Xiao-xue Du, Shu-lin Jiang, Yu Han   +8 more
doaj   +1 more source

Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145

Radiation Oncology, 2021
Background Epidermal Growth Factor Receptor is often overexpressed in advanced prostate carcinoma. In-vitro-studies in prostate carcinoma cell line DU145 have demonstrated increased sensibility to radiation after cetuximab treatment, but clinical data ...
Raik Schneider, Günther Gademann, Hans-Joachim Ochel, Karsten Neumann, Burkhard Jandrig, Peter Hass, Mathias Walke, Martin Schostak, Thomas Brunner, Frank Christoph   +9 more
doaj   +1 more source

Pharmacoproteomic characterisation of human colon and rectal cancer [PDF]

, 2017
Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models for proteome-guided pre-clinical drug sensitivity studies are only beginning to emerge.
Domingo, Enric, Feller, Stephan M, Frejno, Martin, Heinzlmeir, Stephanie, Jarzab, Anna, Jesinghaus, Moritz, Johnstone, Elaine, Kerr, David, Klaeger, Susan, Knapp, Stefan, Koch, Heiner, Kramer, Karl, Kuster, Bernhard, Meng, Chen, Ruprecht, Benjamin, Slotta-Huspenina, Julia, Weichert, Wilko, Wilhelm, Mathias, Zenezini Chiozzi, Riccardo, Zheng, Runsheng   +19 more
core   +1 more source

Primary Tumor Resection in Patients With Unresectable Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis

Annals of Gastroenterological Surgery, EarlyView.
This systematic review and meta‐analysis evaluated the role of primary tumor resection (PTR) in asymptomatic patients with unresectable metastatic colorectal cancer. Across 17 eligible studies including 9317 patients, PTR did not improve overall or progression‐free survival compared with chemotherapy alone.
Junpei Takashima, Hirotoshi Kobayashi, Daisuke Fujimoto, Fumihiko Miura   +3 more
wiley   +1 more source

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. [PDF]

, 2017
The major development of the past decade in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy ...
Ana Ferreira Castro, Athanassios Argiris, Athanassios Argiris, Jeltje Schulten, Kevin J. Harrington, Lisa Licitra, Makoto Tahara, Pauline Chomette   +7 more
core   +3 more sources

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression

Scientific Reports
Colorectal cancer (CRC) often necessitates cetuximab (an EGFR-targeting monoclonal antibody) for treatment. Despite its clinical utility, the specific operative mechanism of cetuximab remains elusive.
Xiaohong Zhang, Wenming Zhou, Chenqu Wu, Jun Jiang, Qianqian Guo, Li Feng, Xun Cheng, Xingxing Zhang   +7 more
doaj   +1 more source